Prospect Therapeutics (nanjing) Limited
Clinical trials sponsored by Prospect Therapeutics (nanjing) Limited, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- First human trial launches for experimental PSTB100 drug Results expected Jun 2027 (estimated)
- Could a new pill help regulate blood sugar? early trial puts PSTC100 to the test Results expected Jul 2027 (estimated)
-
First human trial launches for experimental PSTB100 drug
Knowledge-focused Recruiting nowThis first-in-human study tests the safety and tolerability of PSTB100 tablets in healthy adults aged 18 to 55. Participants receive either a single or multiple doses of the drug or a placebo. Researchers measure how the body absorbs, processes, and eliminates PSTB100 to guide fu…
Phase 1 • Sponsor: Prospect Therapeutics (Nanjing) Limited • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Could a new pill help regulate blood sugar? early trial puts PSTC100 to the test
Knowledge-focused Recruiting nowThis first-in-human trial evaluates the safety and tolerability of an investigational drug called PSTC100, given as tablets to healthy adults aged 18 to 55. Participants receive either the drug or a placebo in increasing doses, and researchers track how the body absorbs, processe…
Phase 1 • Sponsor: Prospect Therapeutics (Nanjing) Limited • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC